# Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

> **NCT01129180** · PHASE1 · COMPLETED · sponsor: **Pierluigi Porcu** · enrollment: 8 (actual)

## Conditions studied

- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Peripheral T-cell Lymphoma
- Post-transplant Lymphoproliferative Disorder
- Prolymphocytic Leukemia
- Recurrent Adult T-cell Leukemia/Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Small Intestine Lymphoma
- T-cell Large Granular Lymphocyte Leukemia

## Interventions

- **DRUG:** azacitidine
- **DRUG:** bortezomib
- **PROCEDURE:** Correlative studies

## Key facts

- **NCT ID:** NCT01129180
- **Lead sponsor:** Pierluigi Porcu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-05
- **Final completion:** 2012-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2013-12-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01129180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01129180, "Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01129180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*